OncLive TV

Julie Renee Brahmer, MD, discusses clinical trials investigating treatment options for patients with non–small cell lung cancer following progression after first-line immunotherapy.

Matthew Galsky, MD, discusses the rationale of the phase 3 CheckMate-274 trial in patients with urothelial cancer.

Bertrand Tombal, MD, PhD, discusses the rationale for conducting a phase 2 study of darolutamide monotherapy in newly diagnosed metastatic hormone-sensitive prostate cancer.

Pallawi Torka, MD, discusses the clinical implications of the FDA approval of pirtobrutinib in patients with relapsed or refractory mantle cell lymphoma.

Carolyn Owen, MD, FRCPC, discusses factors to consider when deciding whether to use the BTK inhibitors ibrutinib, acalabrutinib, or zanubrutinib in patients with chronic lymphocytic leukemia.

Daniel H. Ahn, DO, discusses the evolution of first-line treatments in advanced hepatocellular carcinoma.

Farrukh Awan, MD, discusses the potential use of BTK inhibitors in the management of mantle cell leukemia.

Sergio A. Giralt, MD, discusses the rationale for investigating idecabtagene vicleucel vs standard-of-care regimens in patients with triple-class exposed relapsed/refractory multiple myeloma in the phase 3 Karmma-3 trial.

Nirav N. Shah, MD, discusses the safety of the lentiviral bispecific CAR T cells targeting CD20 and CD19 B-cell antigens, as well as future efforts from a phase 1/2 study of the product in patients with relapsed/refractory mantle cell lymphoma.

Tania Jain, MBBS, discusses the unmet needs for patients with myelofibrosis who receive an allogeneic stem cell transplant.

Daniel H. Ahn, DO, discusses the importance of drug toxicity when selecting between first-line immune checkpoint inhibitor–based regimens in hepatocellular carcinoma.

Chandler Park, MD, MSc, FACP, discusses how the emerging field of radiotheranostics and increasing utilization of biomarker testing will improve the treatment of patients with metastatic hormone-sensitive prostate cancer.

Micheal Foote, MD, discusses the quest to determine optimal sequencing of current therapeutics in the third-line setting and beyond for metastatic colorectal cancer.

Lisa A. Carey MD, ScM, FASCO, discusses the use of response-guided therapy in HER2-positive breast cancer.

Patrick I. Borgen, MD, discusses on the importance of addressing the opioid epidemic through the lens of breast cancer care.

Anees Chagpar, MD, MBA, MPH, FACS, FRCS(C), discusses the unmet needs regarding financial toxicities for patients with breast cancer.

Daniel P. Petrylak, MD, discusses efficacy and safety data from the phase 3 KEYNOTE-921 trial of pembrolizumab and docetaxel in metastatic castrate-resistant prostate cancer.

Steven J. Chmura, MD, PhD, discusses the current management strategies for oligometastatic breast cancer.

Kevin Kalinsky, MD, MS, discusses the evolving treatment landscape for patients with triple-negative breast cancer and how to best sequence antibody-drug conjugates within this population.

Kelly K. Hunt, MD, FACS, FSSO, discusses technical considerations for axillary reverse mapping in breast cancer for the reduction or prevention of lymphedema.

Neil H. Bander, MD, discusses preliminary results from a phase 1/2 study of pembrolizumab in combination with an androgen-receptor signaling inhibitor and alpha-PSMA-targeted radionuclide therapy in mCRPC.

Laura J. Esserman, MD, MBA, discusses the rationale and design for the phase 2 I-SPY2 trial.

Khaled Hassan, MD, discusses the importance of performing precise molecular profiling in patients with lung cancer and the need to identify individually tailored treatment approaches.

Anwaar Saeed, MD, discusses biomarkers that signal the potential efficacy of frontline immunotherapy regimens in patients with advanced esophageal squamous cell carcinoma.

Gregory Vidal, MD, PhD, discusses racial disparities in the treatment of patients with breast cancer.

Anthony Mato, MD, MSCE, discusses recent data on the emerging class of noncovalent BTK inhibitors in chronic lymphocytic leukemia and their potential advantage over currently approved covalent BTK inhibitors.

Anna C. Pavlick, DO, discusses how ongoing research efforts at Weill Cornell Medicine are attempting to ameliorate unmet needs in melanoma.

Phillip J. Koo, MD, discusses ongoing areas of technological and therapeutic advancements within the prostate cancer landscape.

Jonathan Chatzkel, MD, discusses the rationale for the phase Ib/II IMMCO-1 trial investigating the combination of atezolizumab plus tivozanib in metastatic castration-resistant prostate cancer and other immunologically cold tumors.

David A. Braun, MD, PhD, discusses the enrichment of SLAMF7-positive, CD8-positive T-cells and their role on nivolumab resistance in clear cell and non–clear cell renal cell carcinoma.